Key facts
- This page summarizes Henry J. Fuchs's Form 4 filing for BIOMARIN PHARMACEUTICAL INC (BMRN).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 19 Mar 2024, 20:46.
Henry J. Fuchs - 15 Mar 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)
- Reporting relationship
- President, Worldwide R&D
- Issuer ticker
- BMRN
- Reported as of
- 15 Mar 2024
- Net transaction value
- -$2,808,387
- SEC form
- 4
- Accepted by SEC
- 19 Mar 2024, 20:46:14 UTC
- Prior SEC filing
- 07 Mar 2024
- Next SEC filing
- 17 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tae Sang Yoo, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Henry J. Fuchs filed Form 4 for BIOMARIN PHARMACEUTICAL INC (BMRN) on 19 Mar 2024.
Change
- Previous filing in this sequence was filed on 07 Mar 2024.
- Current net transaction value: -$2,808,387.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BMRN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +18,240
- Change %
- +8.6%
- Price
- $0.000000
- Shares after
- 230,357
- Date
- 15 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
BMRN
transaction
Common Stock
Tax liability
- Transaction value
- $2,808,387
- Shares
- -33,485
- Change %
- -15%
- Price
- $83.87
- Shares after
- 196,872
- Date
- 15 Mar 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BMRN
transaction
Derivative
Stock Option (Right to Buy Common Stock)
Award
- Transaction value
- $0
- Shares
- +40,860
- Change %
- Price
- $0.000000
- Shares after
- 40,860
- Date
- 15 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 40,860
- Exercise price
- $83.87
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Restricted stock units granted March 15, 2024. Price not applicable.
Footnote F2
Option grant vests 12/48th on March 15, 2025 and 1/48th on the 15th day of each month thereafter.